BIOGEN IDEC AND MONDOBIOTECH SIGN COLLABORATION AND LICENSING AGREEMENT TO DEVELOP AND COMMERCIALIZE AVIPTADIL FOR PULMONARY ARTERIAL HYPERTENSION

Biogen Idec and mondoBIOTECH AG, a private Swiss biotechnology company, announced the signing of an exclusive collaboration and license agreement for Biogen Idec to develop, manufacture and commercialize Aviptadil, a clinical compound for the treatment of Pulmonary Arterial Hypertension (PAH). BioWire (http://home.businesswire.com/portal/site/biowire2k/index.jsp?epi-content=GENERIC&newsId=20060914005288&ndmHsc=v2*A1157626800000*B1158286522000*DgroupByDate*J2*N1000155&newsLang=en&beanID=760679408&viewID=news_view)